H.C. Wainwright 24th Annual Global Investment Conference
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...
Read MoreCLINUVEL Kommuniqué IV
Seit dem letzten News Communiqué vom 23. Juni hat CLINUVEL die Entwicklung...
Read MoreCLINUVEL Communiqué IV
Melbourne, Australia, 23 August 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read MoreCLINUVEL Kommuniqué III
Seit dem News Communiqué II vom 31. März 2022 hat das Unternehmen...
Read MoreCLINUVEL Communiqué III
Since News Communiqué II on 31 March 2022, the Company has reported...
Read MoreJeffries Healthcare Conference June 2022
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the Jeffries Healthcare...
Read MoreH.C. Wainwright Global Investment Conference 2022
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...
Read MoreStrategic Update IV
CLINUVEL today announced its fourth Strategic Update, focused on the Group’s view...
Read MoreACTH Manufacturing Update
CLINUVEL is progressing scaled manufacturing of adrenocorticotropic hormone (ACTH) under current Good...
Read More